Stock PTIX PROTAGENIC THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Protagenic Therapeutics, Inc.

Equities

PTIX

US74365N2027

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
1.41 USD +1.81% Intraday chart for Protagenic Therapeutics, Inc. +12.80% +42.42%
Apr. 01 Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 27 Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 20.52 14.47 10.88 23.48 6.914 4.391
Enterprise Value (EV) 1 19.91 13.95 11.58 13.43 -0.7204 0.3348
P/E ratio -8.02 x -8.26 x -4.26 x -4.51 x -1.94 x -0.86 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -8.6 x -6.69 x -4.54 x -3.24 x 0.2 x -0.07 x
EV / FCF 482 x -79.8 x -17.9 x -10.4 x 0.99 x -0.14 x
FCF Yield 0.21% -1.25% -5.57% -9.59% 101% -739%
Price to Book -97.3 x -22.8 x -9.46 x 2.4 x 1 x 1.2 x
Nbr of stocks (in thousands) 2,565 2,565 2,590 4,239 4,321 4,435
Reference price 2 8.000 5.640 4.200 5.540 1.600 0.9900
Announcement Date 3/29/19 4/29/20 3/25/21 4/7/22 3/31/23 4/1/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA 1 -2.314 -2.086 -2.551 -4.14 -3.558 -4.499
EBIT 1 -2.314 -2.086 -2.552 -4.14 -3.558 -4.527
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -2.558 -1.751 -2.549 -4.523 -3.556 -5
Net income 1 -2.558 -1.751 -2.549 -4.523 -3.556 -5
Net margin - - - - - -
EPS 2 -0.9970 -0.6825 -0.9861 -1.227 -0.8234 -1.151
Free Cash Flow 1 0.0413 -0.1747 -0.6456 -1.289 -0.728 -2.473
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/29/19 4/29/20 3/25/21 4/7/22 3/31/23 4/1/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - 0.7 - - -
Net Cash position 1 0.61 0.52 - 10.1 7.63 4.06
Leverage (Debt/EBITDA) - - -0.2754 x - - -
Free Cash Flow 1 0.04 -0.17 -0.65 -1.29 -0.73 -2.47
ROE (net income / shareholders' equity) -507% 414% 286% -103% -42.2% -94.5%
ROA (Net income/ Total Assets) -117% -169% -185% -43.3% -23.3% -45.8%
Assets 1 2.191 1.033 1.376 10.43 15.27 10.92
Book Value Per Share 2 -0.0800 -0.2500 -0.4400 2.310 1.600 0.8300
Cash Flow per Share 2 0.1400 0.3100 0.2600 0.1300 0.0500 0.2900
Capex - - - - 0 0.15
Capex / Sales - - - - - -
Announcement Date 3/29/19 4/29/20 3/25/21 4/7/22 3/31/23 4/1/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PROTAGENIC THERAPEUTICS, INC. Stock Protagenic Therapeutics, Inc.
+42.42% 6.14M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.77% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+12.24% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-8.83% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.44% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.01% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.56% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.82% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PTIX Stock
  4. Financials Protagenic Therapeutics, Inc.